Drug Details

General Information of the Drug (ID: DR1364)
Name
SG611-PDCD5
Molecular Type
Gene therapy
Disease Acute lymphoblastic leukemia [ICD-11: 2B33] Investigative [1]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Daunorubicin      Streptomyces peucetius     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [1]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model KG-1a CVCL_1824 Adult acute myeloid leukemia Homo sapiens
MEG-01 CVCL_0425 Chronic myelogenous leukemia Homo sapiens
BV-173 CVCL_0181 Chronic myelogenous leukemia Homo sapiens
SUP-B15 CVCL_0103 B acute lymphoblastic leukemia Homo sapiens
K-562 CVCL_0004 Chronic myelogenous leukemia Homo sapiens
HL-60 CVCL_0002 Adult acute myeloid leukemia Homo sapiens
                    In-vivo Model The triple-regulated CRAd carrying SG611-PDCD5 and nude mouse xenograft models of K562 cells were constructed in this study.
                    Experimental
                    Result(s)		 Treatment with SG611-PDCD5 in combination with low-dose daunorubicin elicited more potent anti-proliferative and proapoptotic effects in leukemic cells in a dose-dependent manner.
Target and Pathway
Target(s) Collagen alpha-1 I (COL1A1)  Molecule Info  [2]
References
Reference 1 Synergistic antitumoral efficacy of a novel replicative adenovirus SG611-PDCD5 and daunorubicin in human leukemic cells. Onco Targets Ther. 2018 Aug 23;11:5121-5132.
Reference 2 Halofuginone: a potent inhibitor of critical steps in angiogenesis progression. FASEB J. 2000 Dec;14(15):2477-85.
 Download Picture         KEGG Link